EP: 2.Initial Treatment Options for Liver-Confined Unresectable HCC EP: 3.Managing Disease Progression After TACE EP: 4.Role of Systemic Therapy in TACE-Eligible Patients EP: 5.Clinical Pearls in Intermediate Stage uHCC Management Video content above is prompted by the following: ...
OsteoblastsCalcium nodulesObjective To investigate the effect of sodium copper chlorophyll on mesenchymal stem cells differentiation into osteoblasts in aplastic anlmia(AA) mice.Methods Sixty AA mice were established and then divided into six groups: normal control group(N),model control group(M),low ...
Joseph Kim, MD, professor of surgery and chief, Division of Surgical Oncology, University of Kentucky Markey Cancer Center, discusses curative therapeutic options in hepatocellular carcinoma (HCC). Curative surgical intervention is considered the best treatment option for eligible patients with HCC, say...
Hepatocellular carcinoma is one of the fastest-growing causes of cancer death in the United States. In this ReCAP, Dr Laura Kulik of Northwestern University discusses the recently expanded options for both first- and second-line treatments. A new first-line treatment became available with the appro...
The aim is to assist clinicians and researchers in gaining a deeper understanding of these diverse treatment options, enabling them to carry out effective treatment and advance their research more efficiently.Similar content being viewed by others Molecular targeted therapy for anticancer treatment ...
Dr Lee on the Rationale for Using Integrative Medicine in Patients With GI Cancers Dr Shroff on the Addition of Nab-Paclitaxel to Gemcitabine/Cisplatin in Biliary Tract Cancer Dr Li on the Casdozokitug/Atezolizumab/Bevacizumab in Unresectable HCC ...
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and deaths due to HCC are increasing in the US [1]. There are a number of treatment options for HCC including surgical resection, liver transplantation, locoregional therapies and systemic therapies [2]. Treatment opti...
Traditional therapeutic approaches such as chemotherapy and radiation therapy have burdened cancer patients with onerous physical and psychological challenges. Encouragingly, the landscape of tumor treatment has undergone a comprehensive and remarkable t
Despite advancements in treatment, current options for HCC, including surgical resection, liver transplantation, locoregional therapies, and systemic treatments, are often limited by late-stage diagnosis and the heterogeneous nature of the disease [8], [9]. Many patients present with advanced disease ...
The FDA has granted amezalpat, a small molecule, oral, selective PPAR⍺ antagonist, fast track designation for the treatment of patients with HCC.1 Findings from the ongoing, phase 1b/2 MORPHEUS-LIVER trial, which were reported in June 2024, support this designation. At a data cutoff date...